ESAIY News and Press, Eisai Co From 01/25/26

FDA Accepts LEQEMBI(R) IQLIK(TM) (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review TOKYO and CAMBRIDGE, Mass., Jan 26, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters...

Eisai Listed as a Global 100 Most Sustainable Corporation for the Tenth Time TOKYO, Jan 21, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has been listed in the 2026 Global 100 Most Sustainable Corporations in the Wo...

2026-01-15 10:13:46 ET Investment Overview When I last covered Biogen Inc. ( BIIB ), the Cambridge, Massachusetts based pharma and central nervous system ("CNS") disease specialist, in a note for Seeking Alpha last February, I awarded its stock my first ever Strong Sell rati...

Eisai and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan TOKYO and NEW YORK, NY., Jan 13, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), a human-c...

Biologics License Application for Subcutaneous Formulation of "LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China TOKYO and CAMBRIDGE, Mass., Jan 6, 2026 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and B...

2025-12-14 22:22:52 ET In a Clinical Trial for Alzheimer’s Disease (CTAD) conference which produced no major advances against the disease, Eisai ( ESALF ) grabbed some of the headlines by suggesting that Leqembi could slow down the progression from mild cognitive impairment t...

2025-12-09 07:17:02 ET Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiatives, ESG, and Dementia Area Contributions December 9, 2025 1:30 AM EST... Read the full article on Seeking Alpha For further details see: Eisai Co., Ltd. (ESAIY) Discusses Value Creation Initiati...

2025-12-04 06:30:00 ET Originally published on November 25, 2025 There have been some interesting failures recently in Alzheimer’s trials. As long-time readers will know, I consider basically all Alzheimer’s drug trials to have failed to one degree or another, and ...

Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025 TOKYO, Dec 2, 2025 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) today announced that new data on anti-tau antibody etalanetug (development code: E2814) was presented at the 18t...

Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status TOKYO and CAMBRIDGE, Mass., Nov 26, 2025 - (JCN New...